Category

• Pipeline2
• Events1

Organizations

• Bausch + Lomb46
• Eyes On Eyecare33
• American Optometric Association25
• Alcon, Inc.23
• Glaukos20
• Harrow20
• Aldeyra Therapeutics16
• Ocuphire Pharma16
• Sight Sciences16
• American Academy Of Ophthalmology15

Tags

• Cell Therapy3
• Clinical Trials3
• Cornea3
• FDA1
• Ophthalmology Tech Forum1
• Genetic Testing1
• Inherited Retinal Disease1
• Injections1
• Ophthalmic Tech1
• Ophthalmology1

• organizations:Aurion Biotech✕

Clear all

Events

KOLs eye the future of genetic engineering and cell transplantation

Industry leaders from four leading ophthalmic companies debut the latest clinical developments in cell-based therapeutics.

Pipeline

FDA grants Breakthrough Therapy Designation, RMAT to Aurion's CED cell therapy

AURN001 is now the first allogeneic cell therapy to be granted two designations for corneal edema secondary to CED.

Pipeline

Aurion doses first Canadian patient in allogeneic cell therapy trial for CED

Corneal endothelial dysfunction candidate is being studied across clinical sites in North America.